Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04701060

Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Resectable Hepatocellular Carcinoma Clinical Trial

Official title:
A Prospective, One-arm, Phase II Clinical Study of Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma With a High Risk of Recurrence

Clinical Trial Summary

This is A prospective, one-arm, phase II clinical study of Camrelizumab combined with apatinib for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04701060
Study type Interventional
Source Tianjin Medical University Cancer Institute and Hospital
Contact
Status Recruiting
Phase Phase 2
Start date January 26, 2021
Completion date February 4, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT03222076 - Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer Phase 2
Recruiting NCT04856046 - Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer
Completed NCT01522820 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Phase 1
Recruiting NCT04857684 - SBRT + Atezolizumab + Bevacizumab in Resectable HCC Early Phase 1
Not yet recruiting NCT05578430 - AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING) Phase 2
Recruiting NCT02379377 - 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant Phase 1
Recruiting NCT04721132 - Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer Phase 2
Completed NCT06013657 - Surgical Resection for Hepatocellular Carcinoma
Recruiting NCT05519410 - Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma Phase 2
Not yet recruiting NCT04834986 - Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma Phase 2
Recruiting NCT05701488 - SIRT With Tremelimumab and Durvalumab for Resectable HCC Phase 1
Withdrawn NCT04965714 - Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer Phase 2
Not yet recruiting NCT05807776 - Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma. Phase 2